References for this Review were found through a search of Pubmed and Medline (January, 1966, to January, 2009), Cochrane Library (January, 1990, to January, 2009) and Embase (January, 1998, to January, 2009). Search terms included “cancer”, “lung cancer”, “breast cancer”, “malignant gliomas”, “gastric cancer”, “MET receptor”, “hepatocyte growth factor”, “scatter factor”, “RON”, “invasive growth”, “metastatic cascade”, “clinical trials”, “EGFR”, “ERBB2”, “ERBB3”, “ERBB4”, “chemotherapy”,
ReviewTargeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors
Introduction
The dissociation and migration of tumour cells, their adhesive interactions with the extracellular matrix, and the proteolysis of extracellular matrix proteins have a key role in tumour progression and metastasis. Deregulation of membrane receptors with tyrosine-kinase activity leads to malignant transformation and resistance to novel anticancer therapies. The hepatocyte growth factor (HGF)–mesenchymal-epithelial transition factor (MET) molecular pathway affects cancer development at different stages, from initiation to metastatic behaviour, in many tumour types.
The epidermal growth factor receptor (EGFR), or ERBB, family is important in carcinogenesis. Among its members, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (ERBB2) are now successfully targeted by biological agents used in cancer therapeutics.1, 2 However, their effectiveness is limited in some patients because of the development of intrinsic or acquired resistance, and there is a need to identify other molecular participants in ERBB-related cellular events. In in-vitro studies of cancer cell lines, cells with an increased gene copy number of EGFR and ERBB2 are dependent on that gene for growth and survival. Some human cancers, such as lung and gastric carcinomas and rhabdomyosarcomas, are also dependent on MET receptor as an absolute requirement for their development and progression.3, 4 MET-related signal transduction is thought to be involved in the development of resistance to EGFR-targeting agents.5, 6, 7
We review the role of MET in carcinogenesis—including strategies to block its pathway in combination with current treatment modalities, especially with anti-EGFR-targeting agents, and consider future perspectives of this rationale in cancer therapeutics.
Section snippets
MET pathway and carcinogenesis
MET was first identified as the protein product of a transforming oncogene, in cultured human osteosarcoma cells (figure 1).8 Isolation of the full-length MET oncogene coding sequence revealed structural features of a membrane receptor with tyrosine-kinase activity.9 HGF, also known as scatter factor, was identified as the natural ligand of MET receptor.10
HGF and MET proteins are processed proteolytically from single-chain precursors into mature disulphide-linked heterodimers. MET is normally
Crosstalk between MET and tyrosine-kinase membrane receptors
MET receptor interacts with other membrane receptors, and many different molecules act as MET partners, including integrin α6β4, the adhesive molecule CD44, class B plexins, FAS, and other tyrosine-kinase receptors such as RON (recepteur d'origine nantais), EGFR, and ERBB2 (figure 3).
Receptors with tyrosin-kinase activity that interact with MET include RON, also known as stem-cell-derived tyrosine kinase in mice.33 RON displays 25% homology with MET in the extracellular region and 63% homology
Strategies for targeting HGF–MET
Various strategies are currently in development to disrupt the HGF–MET signal transduction pathway. Most are being assessed in preclinical animal models or are entering early clinical testing. Before these treatments proceed to large-scale clinical trials, their antitumour activity as a single therapeutic strategy or in combination with other molecularly targeted agents (mainly EGFR inhibitors) should be established, and concerns regarding toxic effects in healthy tissues (eg, liver
EGFR-directed agents
Although the blockade of EGFR function can be accomplished by several methods, two approaches have been most extensively studied: MoAbs against the extracellular receptor domain and small-molecule EGFR-tyrosine-kinase inhibitors.1 However, the clinical application of these compounds has created a number of challenges. The mechanisms of intrinsic or acquired resistance to anti-EGFR therapy are unknown, although many molecular events have been implicated.58 Cumulative evidence suggests that a
Future perspectives
The HGF–MET pathway is a promising target for the development of novel antineoplastic biological agents. Cancers triggered by MET downstream stimuli are governed by different molecular abnormalities. The heterogeneity that characterises MET-related carcinogenesis, along with the documented cross reactions with other membrane-initiated molecular routes, warrants well designed preclinical strategies for finding the best methods of HGF–MET inhibition in human carcinomas. Furthermore, the
Search strategy and selection criteria
References (75)
- et al.
Mutation of the c-Cbl TKB domain binding site on the MET receptor tyrosine kinase converts it into a transforming protein
Mol Cell
(2001) - et al.
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family
Cell
(1994) - et al.
Hepatocyte growth factor receptor tyrosine kinase MET is a substrate of the receptor protein-tyrosine phosphatase DEP-1
J Biol Chem
(2003) - et al.
Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure
J Biol Chem
(2006) - et al.
Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase
J Biol Chem
(2006) - et al.
PAX5 is expressed in small-cell lung cancer and positively regulates c-MET transcription
Lab Invest
(2009) - et al.
Hypoxia promotes invasive growth by transcriptional activation of the MET protooncogene
Cancer Cell
(2003) - et al.
Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumourigenic activities, and potential drug targets
Cancer Lett
(2007) - et al.
Met-related receptor tyrosine kinase Ron in tumour growth and metastasis
Adv Cancer Res
(2008) - et al.
Cross-talk between epidermal growth factor receptor and c-MET signal pathways in transformed cells
J Biol Chem
(2000)
Reactive oxygen species mediate MET receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells
J Biol Chem
The Sema domain of MET is necessary for receptor dimerization and activation
Cancer Cell
Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions
J Biol Chem
High-throughput analysis of HGF-stimulated cell scattering
J Biomol Screen
A new MET inhibitory-scaffold identified by a focused forward chemical biological screen
Biochem Biophys Res Commun
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
Differentiation
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Lancet Oncol
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
Ann Oncol
Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and epidermal growth factor receptor (EGFR) family expression
Cancer Lett
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas
JAMA
Trastuzumab—mechanism of action and use in clinical practice
N Engl J Med
Validation of MET as a therapeutic target in alveolar and embryonal rhabdomyosarcoma
Cancer Res
Lung cancer cell lines harboring MET gene amplification are dependent on MET for growth and survival
Cancer Res
MET receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
Cancer Res
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Science
Coactivation of receptor tyrosine kinases affects the response of tumour cells to targeted therapies
Science
Molecular cloning of a new transforming gene from a chemically transformed human cell line
Nature
Tyrosine kinase receptor indistinguishable from the c-MET protein
Nature
Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the prot-oncogene c-MET
Oncogene
c-MET is essential for wound healing in the skin
J Cell Biol
Cell cycle effects resulting from inhibition of hepatocyte growth factor and its receptor c-MET in regenerating rat livers by RNA interference
Hepatology
The MET tyrosine kinase receptor in development and cancer
Cancer Metastasis Rev
Gab1 phosphorylation: a novel mechanism for negative regulation of HGF receptor signaling
Oncogene
The role of STATs in lung carcinogenesis: an emerging target for novel therapeutics
J Mol Med
Receptor trafficking controls weak signal delivery: a strategy used by c-MET for STAT3 nuclear accumulation
J Cell Biol
Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets
Nat Rev Drug Discov
The crossroads of oncogenesis and metastasis
N Engl J Med
Cited by (111)
Bispecific antibody drug conjugates: Making 1+1>2
2024, Acta Pharmaceutica Sinica BPhase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors
2023, JTO Clinical and Research ReportsPhosphoproteomic Analysis of FLCN Inactivation Highlights Differential Kinase Pathways and Regulatory TFEB Phosphoserines
2022, Molecular and Cellular ProteomicsDesign, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidine derivatives containing 1,8-naphthyridine-4-one fragment
2021, European Journal of Medicinal ChemistryCitation Excerpt :c-Met belongs to a subfamily of receptor tyrosine kinases (RTKs) encoded by the c-Met proto-oncogene, which was discovered in human osteosarcoma cell lines [9,10]. The binding of hepatocyte growth factor (HGF) to c-Met induces a series of effects, including proliferation, angiogenesis, invasion and migration, which are essential in normal physiology [11,12]. However, the abnormal activation of c-Met occurs in many types of human cancers, such as breast, liver, gastric cancers and so on [13–15].
Combinatorial approaches targeting the EGFR family and c-Met in SCCHN
2021, Oral OncologyADAM proteases: Emerging role and targeting of the non-catalytic domains
2019, Cancer Letters